Abstract
Many herbal medicines and drugs are available in the clinic as potent hepatoprotective agents for the treatment of commonly occurring liver diseases. Recently, herbal medicines such as silymarin and curcumin have gained more attention and popularity for the treatment of various liver diseases because of their safety and efficacy profiles. Some of them are related to transporters for drug disposition processes, therapeutic efficacy and/or adverse drug reactions. Currently, herbal medicines and diet supplements made from natural products are widely used in patients who are being treated with conventional prescription medicines, which are related to an increasing risk of herbal-drug interactions (HDIs) and/or drug–drug interactions (DDIs). The purpose of present review is to summarize the contemporary knowledge of transporter-mediated HDIs or DDIs for herbal medicines/drugs focusing on hepatoprotective compounds. Several herbal medicines/drugs are discussed in detail in this review.
Keywords: ABC transporters, drug-drug interaction, herbal-drug interaction, herbal medicine, liver protective drug, SLC transporters.
Current Drug Metabolism
Title:Interactions between Transporters and Herbal Medicines/Drugs: A Focus on Hepatoprotective Compounds
Volume: 16 Issue: 10
Author(s): Aijie Zhang, Quansheng Li, Xin He, Duanyun Si and Changxiao Liu
Affiliation:
Keywords: ABC transporters, drug-drug interaction, herbal-drug interaction, herbal medicine, liver protective drug, SLC transporters.
Abstract: Many herbal medicines and drugs are available in the clinic as potent hepatoprotective agents for the treatment of commonly occurring liver diseases. Recently, herbal medicines such as silymarin and curcumin have gained more attention and popularity for the treatment of various liver diseases because of their safety and efficacy profiles. Some of them are related to transporters for drug disposition processes, therapeutic efficacy and/or adverse drug reactions. Currently, herbal medicines and diet supplements made from natural products are widely used in patients who are being treated with conventional prescription medicines, which are related to an increasing risk of herbal-drug interactions (HDIs) and/or drug–drug interactions (DDIs). The purpose of present review is to summarize the contemporary knowledge of transporter-mediated HDIs or DDIs for herbal medicines/drugs focusing on hepatoprotective compounds. Several herbal medicines/drugs are discussed in detail in this review.
Export Options
About this article
Cite this article as:
Zhang Aijie, Li Quansheng, He Xin, Si Duanyun and Liu Changxiao, Interactions between Transporters and Herbal Medicines/Drugs: A Focus on Hepatoprotective Compounds, Current Drug Metabolism 2015; 16 (10) . https://dx.doi.org/10.2174/1389200216666150812124359
DOI https://dx.doi.org/10.2174/1389200216666150812124359 |
Print ISSN 1389-2002 |
Publisher Name Bentham Science Publisher |
Online ISSN 1875-5453 |
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
- Announcements
Related Articles
-
Cationic Lipophilic Radiotracers for Functional Imaging of Multidrug Resistance
Current Radiopharmaceuticals USP48 Sustains Chemoresistance and Metastasis in Ovarian Cancer
Current Cancer Drug Targets Oxidative Stress and Cancer: The Role of Nrf2
Current Cancer Drug Targets Computational Design, Organic Synthesis, and Biological Evaluation of Polyphenol Proteasome Inhibitors: Significance in Drug Discovery and Cancer Prevention
Drug Design Reviews - Online (Discontinued) The Role of Genistein and Synthetic Derivatives of Isoflavone in Cancer Prevention and Therapy
Mini-Reviews in Medicinal Chemistry Gene Sets of Gene Ontology are More Stable Diagnostic Biomarkers than Genes in Oral Squamous Cell Carcinoma
Current Bioinformatics Editorial [Hot Topic: Protein Targets in the Treatment of Cancers (Guest Editor: Sabbir Ahmed)]
Anti-Cancer Agents in Medicinal Chemistry Molecular Chaperone ORP150 in ER Stress–related Diseases
Current Pharmaceutical Design Gene Expression Signatures of Lymph Node Metastasis in Oral Cancer: Molecular Characteristics and Clinical Significances
Current Cancer Therapy Reviews Patent Selections
Recent Patents on Regenerative Medicine Clinical Pharmacology of Novel Selective COX-2 Inhibitors
Current Pharmaceutical Design Overview of Flaxseed Patent Applications for the Reduction of Cholesterol Levels
Recent Patents on Food, Nutrition & Agriculture MicroRNA-34a and its target genes: Key factors in cancer multidrug resistance
Current Pharmaceutical Design Methionine-Derived Metabolites in Apoptosis: Therapeutic Opportunities for Inhibitors of their Metabolism in Chemoresistant Cancer Cells
Current Medicinal Chemistry Immunobiology of Antigen-Specific Immunoglobulin Free Light Chains in Chronic Inflammatory Diseases
Current Pharmaceutical Design Design, Synthesis, <i>In Silico</i> and <i>In Vitro</i> Evaluation of Novel Pyrimidine Derivatives as EGFR Inhibitors
Anti-Cancer Agents in Medicinal Chemistry Cigarette Smoke Decreases Salivary 18 kDa Translocator Protein Binding Affinity – in Association with Oxidative Stress
Current Medicinal Chemistry “Letting the Air In” Can Set the Stage for Tumor Recurrences
Current Cancer Therapy Reviews On the Use of Topological Features of Metabolic Networks for the Classification of Cancer Samples
Current Genomics The Therapeutic Potential of RNA Interference: Novel Approaches for Cancer Treatment
Current Pharmaceutical Biotechnology